Tenet Healthcare (NYSE:THC) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen cut shares of Tenet Healthcare (NYSE:THC) from a strong-buy rating to a buy rating in a research report report published on Saturday morning.

Other research analysts also recently issued reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tenet Healthcare in a research note on Monday, July 27th. Robert W. Baird raised their target price on Tenet Healthcare from $210.00 to $280.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 28th. Morgan Stanley upped their price target on Tenet Healthcare from $254.00 to $274.00 and gave the company an “overweight” rating in a research report on Monday, July 27th. Mizuho set a $290.00 target price on Tenet Healthcare in a research note on Monday, August 10th. Finally, Piper Sandler set a $308.00 price target on Tenet Healthcare in a research note on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Tenet Healthcare currently has a consensus rating of “Moderate Buy” and a consensus price target of $273.00.

Tenet Healthcare Trading Up 0.1%

Shares of THC stock opened at $267.23 on Friday. Tenet Healthcare has a 12-month low of $157.58 and a 12-month high of $270.57. The company has a quick ratio of 1.35, a current ratio of 1.41 and a debt-to-equity ratio of 2.00. The business has a 50-day moving average price of $210.20 and a two-hundred day moving average price of $203.93. The firm has a market cap of $21.52 billion, a P/E ratio of 10.31, a price-to-earnings-growth ratio of 1.02 and a beta of 1.23.

Tenet Healthcare (NYSE:THC) last posted its quarterly earnings results on Thursday, July 23rd. The company reported $6.12 EPS for the quarter, topping the consensus estimate of $4.26 by $1.86. The firm had revenue of $6.04 billion for the quarter, compared to the consensus estimate of $5.43 billion. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The business’s revenue was up 6.8% compared to the same quarter last year. During the same period last year, the firm posted $4.02 earnings per share. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. Equities analysts anticipate that Tenet Healthcare will post 20.97 EPS for the current fiscal year.

Insider Transactions at Tenet Healthcare

In other news, Director J Robert Kerrey sold 5,638 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $174.52, for a total transaction of $983,943.76. Following the sale, the director owned 16,804 shares in the company, valued at $2,932,634.08. This represents a 25.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Paola M. Arbour sold 10,878 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $243.90, for a total transaction of $2,653,144.20. Following the sale, the executive vice president directly owned 18,413 shares of the company’s stock, valued at $4,490,930.70. This trade represents a 37.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 41,375 shares of company stock valued at $9,793,347. 0.97% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Tenet Healthcare

Large investors have recently bought and sold shares of the business. PeakShares LLC lifted its position in Tenet Healthcare by 3.3% during the first quarter. PeakShares LLC now owns 1,693 shares of the company’s stock valued at $319,000 after purchasing an additional 54 shares during the period. Sanctuary Advisors LLC grew its position in Tenet Healthcare by 0.5% in the 1st quarter. Sanctuary Advisors LLC now owns 11,900 shares of the company’s stock worth $2,246,000 after purchasing an additional 57 shares during the period. Quadrant Capital Group LLC lifted its holdings in shares of Tenet Healthcare by 0.7% during the 4th quarter. Quadrant Capital Group LLC now owns 8,134 shares of the company’s stock valued at $1,616,000 after buying an additional 58 shares during the period. Applied Finance Capital Management LLC boosted its stake in shares of Tenet Healthcare by 3.8% in the 1st quarter. Applied Finance Capital Management LLC now owns 1,644 shares of the company’s stock worth $310,000 after buying an additional 60 shares during the last quarter. Finally, Syon Capital LLC grew its holdings in shares of Tenet Healthcare by 5.3% in the fourth quarter. Syon Capital LLC now owns 1,254 shares of the company’s stock worth $249,000 after acquiring an additional 63 shares during the period. 95.44% of the stock is currently owned by institutional investors.

Trending Headlines about Tenet Healthcare

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Analyst estimates increased across multiple periods. Zacks Research raised its FY2026 EPS forecast to $20.32 from $17.52, FY2027 to $18.91 from $17.17, and FY2028 to $20.09 from $17.99. The firm also lifted quarterly estimates, including Q4 2026 to $5.04 from $4.47, Q2 2027 to $4.66 from $4.17, Q3 2027 to $4.50 from $4.06, Q4 2027 to $5.13 from $4.62, and Q2 2028 to $5.35 from $4.71. MarketBeat analyst estimate reports
• Positive Sentiment: Near-term and longer-term earnings expectations are improving. Zacks also raised its Q3 2026 EPS estimate to $4.34 from $4.13, Q1 2027 to $4.63 from $4.32, and Q1 2028 to $4.52 from $4.10. The revisions suggest stronger anticipated operating performance and provide a positive catalyst for THC. Zacks Tenet Healthcare valuation analysis
• Neutral Sentiment: Valuation remains a focus. Zacks questioned whether investors are undervaluing Tenet, while a separate analysis noted that the stock has reached a 52-week high and considered whether additional upside remains. These reports support investor interest but also highlight that expectations may already reflect much of the recent rally. Zacks fresh high analysis
• Negative Sentiment: Wall Street Zen lowered its rating to “Buy.” Although the revised rating remains positive, the downgrade indicates reduced conviction compared with its prior recommendation. Wall Street Zen rating report

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.